S 895
107th Congress
Senate
Taxation
AIDS (Disease)
Access to health care
Biotechnology
Business and social problems
Business income tax
Clinical trials
Commerce
Communicable diseases
Congress
Congressional reporting requirements
Developing countries
Drug industry
Economics and Public Finance
Government Operations and Politics
Government and business
Government trust funds
Governmental investigations
Health
Human immunodeficiency viruses
Vaccines for the New Millennium Act of 2001
Introduced: May 16, 2001
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 16, 2001
Read twice and referred to the Committee on Finance.
May 16, 2001
Sponsor introductory remarks on measure. (CR S5008-5009)
May 16, 2001
Introduced in Senate
Plain-English summary
Vaccines for the New Millennium Act of 2001 - Amends the Internal Revenue Code to allow a limited business credit for the costs medical research related to developing vaccines against widespread diseases. Defines Widespread diseases as malaria, tuberculosis, HIV, or any infectious disease (of a single etiology) which, according to the World Health Organization, causes over one million human deaths annually.
Allows a limited lifesaving vaccine sale credit equal to the amount of qualified vaccine sales. Defines qualified vaccine sales as the aggregate amount paid to the taxpayer for a qualified sale. Defines a qualified sale as a sale of a qualified vaccine: (1) to a nonprofit organization or to a government of any foreign country (or instrumentality of such a government); and (2) for distribution in a developing country.
Establishes the Lifesaving Vaccine Purchase Fund.
Expresses the sense of Congress concerning the manufacture, distribution, support for global efforts, and tiered pricing of vaccines.
What's happening now
Read twice and referred to the Committee on Finance.
Committees of jurisdiction
1
Cosponsors
1